Oral propranolol therapy in 23 infants with infantile hemangioma.
- Author:
Jaeyoon KIM
1
;
Jong Won HONG
;
Tai Suk ROH
;
Won Jai LEE
Author Information
- Publication Type:Original Article
- Keywords: Hemangioma; Propranolol; Therapeutics
- MeSH: Cohort Studies; Extremities; Female; Head; Hemangioma*; Humans; Infant*; Male; Neck; Parturition; Propranolol*
- From:Archives of Plastic Surgery 2018;45(6):517-524
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Infantile hemangioma (IH) is a common vascular tumor in pediatric patients, and is commonly treated with propranolol. We describe our experiences with dosage, response to treatment, and side effects in 23 IH patients treated with propranolol. METHODS: For this nonrandomized comparative cohort study, the authors enrolled 23 patients treated with propranolol. Photographs were taken before propranolol administration and at 3, 6, 9, and 12 months after treatment. Treatment responses were objectively analyzed with a computer program. RESULTS: There were three male and 20 female patients. Common tumor locations were the head and neck (13 cases, 56.5%), trunk (four cases, 17.4%), extremities (three cases, 13.0%), and combined locations (three cases, 13.0%). The response to propranolol was significantly lower in patients with two or more lesions than in patients with a single lesion in terms of both color fading (P < 0.001) and size reduction (P < 0.001). In male patients (42.2±3.9), the change in a-values, indicating coloration, was higher than in female patients (19.8 ±13.8)(P < 0.001). In patients who started treatment before 6 months after birth, the size reduction was greater than in their counterparts (62.3%; range, 3.0%–93.0% vs. 15.8%; range, 1.0%–79.0%; P < 0.001). CONCLUSIONS: Propranolol is an efficacious treatment with a good safety profile. In patients with a single lesion, the response to treatment was better in terms of color fading and size reduction. Furthermore, male patients responded better to propranolol treatment in terms of color fading than female patients, and starting treatment before 6 months after birth was more advantageous for size reduction.
